Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 18/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12106778 | 1.00 | ITGB3 (0.41) | ITGB3ITGA2BDRD3SLC6A3ITGAV | |
| SCHEMBL10044115 | 1.00 | ITGB3 (0.41) | ITGB3ITGA2BDRD3SLC6A3ITGAV | |
| SCHEMBL12106888 | 0.87 | ITGB3 (0.44) | ITGB3ITGA2B | |
| SCHEMBL12106774 | 0.87 | ITGB3 (0.44) | ITGB3ITGA2B | |
| SCHEMBL10044105 | 0.85 | ITGB3 (0.42) | ITGB3ITGA2B | |
| SCHEMBL13534979 | 0.83 | ITGB3 (0.45) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL12106777 | 0.80 | ITGB3 (0.41) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL1295462 | 0.80 | GPR119 (0.48) | CHRM2 | |
| SCHEMBL1295465 | 0.80 | GPR119 (0.48) | CHRM2 | |
| SCHEMBL1296340 | 0.80 | GPR119 (0.48) | CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | GPR119, GPR27, GLP1R | ITGB3 3442/4885ITGA2B 3353/4885DRD3 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.